Video

Dr Leslie Citrome on Coverage of Metabolic-Friendly Antipsychotics

Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.

Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.

Transcript

What is the landscape like for patients trying to get coverage for atypical antipsychotis that cause fewer metabolic side effects?

We do have choices in terms of the array of antipsychotics that are available for the treatment of schizophrenia. Some may be more metabolically friendly than others. But they tend to be branded products, and so more costly. But it's not usually an impossibility to get them for our patients. I don't see huge obstacles in prescribing branded, atypical antipsychotics where they would be needed.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Dr Bonnie Qin
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo